Sofosbuvir is a patented hepatitis C drug developed by Gilead Science US, the product is approved by US FDA in December 2013, by EDQM in January 2014. Sofosbuvir is the first approved oral medicine for hepatitis C, and the first medicine reached $10 billion sales in the same year of approval. Key intermediates of Sofosbuvir manufactured by Yongtai is patented, also Yongtai is the largest supplier of such product globally.
Additionally, company invested Yongtai Pharmaceutial for pharmaceutical formulation manufacturing, established R&D center in US Medicine Valley to apply and sell generic drugs. Yongtai is building vertical integration layout from intermediates to formulation, relying on Yongtai’s fluorinated intermediates manufacturing advantages.